Streetbeat News

Price Targets

EFTR

HC Wainwright & Co. analyst Robert Burns has maintained a Buy rating on eFFECTOR Therapeutics (NASDAQ:EFTR) and adjusted the price target to $24 from $5, indicating a strong positive outlook for the company.

Portfolio Pulse from Benzinga Newsdesk

February 06, 2024 | 4:02 pm

PLTR

RBC Capital analyst Rishi Jaluria reiterates an Underperform rating on Palantir Technologies (PLTR) and maintains a $5 price target.

Portfolio Pulse from Benzinga Newsdesk

February 06, 2024 | 4:00 pm

AXS

Axis Capital Holdings (NYSE:AXS) has been analyzed by 4 analysts, showing a diverse range of perspectives with recent ratings ranging from bullish to bearish. The average 12-month price target is $68.75, indicating a 6.18% increase from the previous target of $64.75. Analysts from Keefe, Bruyette & Woods, UBS, and Wells Fargo have adjusted their price targets and ratings, reflecting a dynamic view on the company's performance. Despite the positive adjustments in analyst ratings, Axis Capital Holdings faces financial challenges, including a -4.96% decline in revenue growth, a net margin of -10.64%, and an ROE of -3.27%, indicating potential difficulties in maintaining profitability and efficiently utilizing assets.

Portfolio Pulse from Benzinga Insights

February 06, 2024 | 4:00 pm

NOV

A comprehensive analysis of 5 analyst recommendations for NOV (NYSE:NOV) reveals a mixed sentiment, with recent ratings ranging from bullish to indifferent. Over the past quarter, the sentiment has shifted towards a more cautious stance, with the latest 30-day period showing an indifferent rating. Analysts have adjusted their 12-month price targets for NOV, resulting in an average target of $25.8, down 7.86% from the previous average. Key analysts from RBC Capital, Stifel, Raymond James, TD Cowen, and JP Morgan have made various adjustments to their ratings and price targets, reflecting their views on NOV's market performance and future prospects. NOV, a leading supplier in the oil and gas industry, has shown positive revenue growth and strong financial health indicators such as net margin, ROE, and ROA, despite a market capitalization below industry averages.

Portfolio Pulse from Benzinga Insights

February 06, 2024 | 4:00 pm

MCD

RBC Capital analyst Christopher Carril maintains an Outperform rating on McDonald's (MCD) but lowers the price target from $340 to $335.

Portfolio Pulse from Benzinga Newsdesk

February 06, 2024 | 3:55 pm

MCD

Barclays analyst Jeffrey Bernstein maintains an Overweight rating on McDonald's (MCD) but lowers the price target from $343 to $340.

Portfolio Pulse from Benzinga Newsdesk

February 06, 2024 | 3:53 pm

EMN

RBC Capital analyst Arun Viswanathan maintains a Sector Perform rating on Eastman Chemical (EMN) and lowers the price target from $91 to $89.

Portfolio Pulse from Benzinga Newsdesk

February 06, 2024 | 3:53 pm

WWD

Barclays analyst David Strauss maintains an Equal-Weight rating on Woodward (NASDAQ:WWD) and raises the price target from $134 to $140.

Portfolio Pulse from Benzinga Newsdesk

February 06, 2024 | 3:52 pm

VRTX

Barclays analyst Gena Wang has maintained an Overweight rating on Vertex Pharmaceuticals (NASDAQ: VRTX) and increased the price target from $446 to $472. This adjustment reflects a positive outlook on the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

February 06, 2024 | 3:51 pm

ARES

RBC Capital analyst Kenneth Lee maintains an Outperform rating on Ares Management (NYSE:ARES) and raises the price target from $120 to $135.

Portfolio Pulse from Benzinga Newsdesk

February 06, 2024 | 3:51 pm